6月28日(ri)，由国(guo)(guo)药集团中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)药控股(gu)有(you)限公司主办、中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)药有(you)限公司承办，中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)医科(ke)学院(yuan)(yuan)中(zhong)(zhong)药研究所、中(zhong)(zhong)国(guo)(guo)电子技术标准化研究院(yuan)(yuan)提供技术支持(chi)的“2022年产业技术基础公共服务平台项目(mu)——中(zhong)(zhong)药全产业链质量技术服务平台”建(jian)设项目(mu)推(tui)进(jin)会在北京召(zhao)开。
中(zhong)(zhong)国(guo)(guo)科(ke)学院院士、中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)医科(ke)学院首(shou)席研究员(yuan)仝小林等与会专(zhuan)家(jia)(jia)围绕“中(zhong)(zhong)药(yao)全(quan)产(chan)业链质(zhi)量技术服(fu)务平(ping)(ping)台(tai)”建设(she)项目实(shi)施方案进行了座谈交流。工业和信(xin)息化(hua)部消费品工业司司长(zhang)何亚琼(qiong)，国(guo)(guo)家(jia)(jia)中(zhong)(zhong)医药(yao)管理局科(ke)技司二级巡视员(yuan)马忠明，中(zhong)(zhong)国(guo)(guo)医药(yao)集团有(you)限(xian)公司副(fu)(fu)总(zong)经(jing)理董增贺，中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)药(yao)协会常务副(fu)(fu)会长(zhang)吴宪(xian)，人民日报(bao)社健(jian)康时报(bao)副(fu)(fu)总(zong)编辑(ji)王君平(ping)(ping)，中(zhong)(zhong)国(guo)(guo)中(zhong)(zhong)药(yao)控股有(you)限(xian)公司董事长(zhang)陈映龙等出(chu)席会议(yi)。
何亚琼强调，要(yao)充分认识加强中(zhong)药(yao)质量(liang)公共(gong)服务能力建(jian)设(she)的(de)重要(yao)意义(yi)，推动解(jie)决制约中(zhong)药(yao)行业(ye)发(fa)(fa)展(zhan)(zhan)的(de)突出问题，促进产业(ye)健康(kang)发(fa)(fa)展(zhan)(zhan)；发(fa)(fa)挥企业(ye)自身(shen)优势，引入(ru)互(hu)联网(wang)、大(da)数据(ju)领(ling)域资源(yuan)，服务行业(ye)、赋能行业(ye)，切实(shi)提升(sheng)(sheng)中(zhong)药(yao)全(quan)产业(ye)链(lian)质量(liang)技术公共(gong)服务水(shui)平(ping)，确保“公共(gong)”属(shu)性；通过项(xiang)目(mu)平(ping)台的(de)搭建(jian)，提高(gao)中(zhong)药(yao)全(quan)产业(ye)链(lian)的(de)质控水(shui)平(ping)，切实(shi)提升(sheng)(sheng)中(zhong)药(yao)产品质量(liang)，全(quan)力保障(zhang)人民群(qun)众健康(kang)需求。
仝小林表示，“中(zhong)(zhong)药(yao)(yao)全产(chan)业(ye)链(lian)(lian)质(zhi)量技术服(fu)务(wu)平台”建设项目系统整合中(zhong)(zhong)药(yao)(yao)全产(chan)业(ye)链(lian)(lian)产(chan)品开发、检(jian)验检(jian)测、质(zhi)量控制和质(zhi)量追(zhui)溯等实体及数字资源(yuan)，促进中(zhong)(zhong)药(yao)(yao)创新链(lian)(lian)与产(chan)业(ye)链(lian)(lian)的深度融合、激发中(zhong)(zhong)药(yao)(yao)企(qi)业(ye)创新活力(li)，助(zhu)力(li)中(zhong)(zhong)药(yao)(yao)产(chan)业(ye)高质(zhi)量发展。
董(dong)增贺表示，中国中药(yao)控股作为国药(yao)集团实现(xian)“四梁八柱、百强(qiang)万(wan)亿(yi)”总体(ti)(ti)(ti)战略规划(hua)目(mu)标的重要(yao)(yao)组成部分，要(yao)(yao)以本项(xiang)目(mu)实施为契(qi)机，组建协同产业链网络(luo)，强(qiang)化内外战略联盟，建设数字(zi)化产学研融合服(fu)务平台(tai)和协同创(chuang)(chuang)新网络(luo)，着力构筑(zhu)“立体(ti)(ti)(ti)式”中药(yao)产业科(ke)技创(chuang)(chuang)新和质量服(fu)务格局，整体(ti)(ti)(ti)联动(dong)推动(dong)全国中药(yao)产业体(ti)(ti)(ti)系高质量发(fa)展(zhan)。
陈映龙(long)表示，中(zhong)(zhong)(zhong)国(guo)中(zhong)(zhong)(zhong)药(yao)控股作为国(guo)药(yao)集团(tuan)现(xian)代中(zhong)(zhong)(zhong)药(yao)板块的(de)核(he)心(xin)平台(tai)，肩负着践行(xing)国(guo)家中(zhong)(zhong)(zhong)医药(yao)发(fa)展战(zhan)略，引(yin)领中(zhong)(zhong)(zhong)药(yao)产(chan)业高质量(liang)发(fa)展的(de)使命和责任。公司(si)的(de)发(fa)展战(zhan)略与项目目标深(shen)度契合(he)，中(zhong)(zhong)(zhong)国(guo)中(zhong)(zhong)(zhong)药(yao)控股将带(dai)动联(lian)合(he)体成员单位，不断推(tui)进(jin)中(zhong)(zhong)(zhong)医药(yao)产(chan)业数字化与产(chan)业升级，让中(zhong)(zhong)(zhong)医药(yao)在新(xin)时(shi)代焕发(fa)出新(xin)的(de)光彩！
“中(zhong)(zhong)药(yao)(yao)(yao)(yao)全产(chan)(chan)业(ye)(ye)(ye)链质(zhi)量(liang)技术服(fu)(fu)务(wu)平台”建设项目(mu)由“中(zhong)(zhong)药(yao)(yao)(yao)(yao)全产(chan)(chan)业(ye)(ye)(ye)链质(zhi)量(liang)可(ke)追溯(su)数据平台”“中(zhong)(zhong)药(yao)(yao)(yao)(yao)全过程质(zhi)量(liang)控制检验(yan)检测平台”“中(zhong)(zhong)药(yao)(yao)(yao)(yao)创新成果产(chan)(chan)业(ye)(ye)(ye)化公共(gong)服(fu)(fu)务(wu)平台”三部分构成，共(gong)建三位一体(ti)的数字化中(zhong)(zhong)药(yao)(yao)(yao)(yao)全产(chan)(chan)业(ye)(ye)(ye)链数据信(xin)息系(xi)统(tong)。项目(mu)建成后将为行业(ye)(ye)(ye)提供中(zhong)(zhong)药(yao)(yao)(yao)(yao)产(chan)(chan)业(ye)(ye)(ye)管(guan)理、中(zhong)(zhong)药(yao)(yao)(yao)(yao)新药(yao)(yao)(yao)(yao)开发、检验(yan)检测服(fu)(fu)务(wu)、快速(su)检测服(fu)(fu)务(wu)、中(zhong)(zhong)药(yao)(yao)(yao)(yao)大品(pin)种二次开发、追溯(su)数字化服(fu)(fu)务(wu)、药(yao)(yao)(yao)(yao)理药(yao)(yao)(yao)(yao)效和(he)安全性评价、质(zhi)量(liang)管(guan)理体(ti)系(xi)建设服(fu)(fu)务(wu)、知识(shi)服(fu)(fu)务(wu)、成果转化服(fu)(fu)务(wu)、中(zhong)(zhong)药(yao)(yao)(yao)(yao)产(chan)(chan)品(pin)或企业(ye)(ye)(ye)评价等(deng)服(fu)(fu)务(wu)。（朱文）
（责任编辑：郭(guo)文培）
